Aclarion Inc. Advances AI‑Driven Chronic Low Back Pain Assessment with New U.S. Patent and Industry Awards

Aclarion Inc. (Nasdaq: ACON, ACONW) announced that it has secured a U.S. patent for a scalable, artificial‑intelligence (AI)–driven method of assessing chronic low back pain (cLBP). The patent, issued on 16 April 2026, protects the company’s proprietary algorithms that analyze magnetic resonance spectroscopy (MRS) data to identify biomarkers indicative of discogenic pain.

Patent Significance

The newly granted U.S. patent expands Aclarion’s intellectual‑property portfolio around its flagship platform, Nociscan. Nociscan leverages MRS to capture the chemical milieu of intervertebral discs, then applies proprietary AI to classify discs as painful or non‑painful. The patent’s emphasis on scalability and cloud‑based deployment underscores Aclarion’s strategy of rapid, infrastructure‑agnostic adoption across imaging centers and health systems.

Industry Recognition

Earlier in April, Aclarion received a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category from the Pinnacle Awards. This accolade followed its selection as a 2025 HLTH Digital Health Award winner for Nociscan, a solution praised for its potential to transform the evaluation and management of discogenic low back pain. These awards reinforce external validation of Aclarion’s mission to embed objective, biomarker‑based data into routine clinical decision‑making.

Clinical Impact

According to Aclarion, Nociscan has demonstrated a 97 % surgical success rate when all Nociscan‑positive discs are treated. The platform’s objective biochemical data complement traditional imaging, clinical assessment, and physician expertise, offering a more precise framework for treatment planning in a condition that affects an estimated 266 million people worldwide.

Market Context

  • Stock Performance: As of 14 April 2026, Aclarion’s share price stood at $3.20, trailing its 52‑week low of $2.34 and well below its 52‑week high of $12.03.
  • Valuation: The company’s market cap is $7.24 million, with a price‑to‑earnings ratio of –0.26, reflecting its early‑stage revenue profile.
  • Strategic Position: With the patent secured, Aclarion is poised to deepen penetration among spine specialists seeking objective tools, while maintaining a cloud‑based delivery model that facilitates rapid scaling without new hardware investments.

Forward‑Looking Outlook

The convergence of a robust patent, industry recognition, and a clinically validated platform positions Aclarion to capitalize on the substantial market opportunity presented by chronic low back pain. Continued adoption of Nociscan is likely to drive revenue growth, while the scalable AI framework may enable expansion into other musculoskeletal and neurological indications. The company’s focus on delivering measurable clinical outcomes through biomarker analysis aligns with broader trends toward precision medicine and value‑based care, suggesting a favorable trajectory for stakeholders who support its mission.